SYNALAR (fluocinolone acetonide) by Eurofarma Laboratórios is corticosteroid hormone receptor agonists [moa]. First approved in 1963.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
SYNALAR (fluocinolone acetonide) is a potent topical corticosteroid approved in 1963 that works as a corticosteroid hormone receptor agonist to reduce inflammation and immune response. It is indicated for inflammatory and pruritic dermatological conditions requiring topical corticosteroid therapy. The ointment formulation is applied directly to affected skin areas.
As LOE approaches, the brand team is likely consolidating around defensive strategies and cost management rather than growth investments.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant
Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study
Worked on SYNALAR at Eurofarma Laboratórios? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on SYNALAR offers limited growth trajectory but provides stable, foundational experience in managing a legacy dermatology asset in a competitive generic environment. Career advancement requires excellence in cost management, payer relations, and market access rather than innovation or clinical expertise.